Sign up
Pharma Capital

Bioxyne gets ready to raise

The halt will remain in place until Wednesday 19th April 2017.
Bioxyne has a focus on immune health and immunotherapeutic products

Bioxyne (ASX:BXN) has been granted a trading halt by the ASX, pending details of a capital raising.

The halt will remain in place until the opening of trade on Wednesday 19th April 2017, or earlier if an announcement is made to the market.

View full BXN profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.